Dr. Richard DiMarchi: The Evolution of GLP-1 Science | Ep. 10

Dr. Richard DiMarchi: The Evolution of GLP-1 Science | Ep. 10

In this episode of The GLP-1 Podcast Show, I speak with Dr. Richard DiMarchi, Distinguished Professor at Indiana University and a pioneer in peptide therapeutics, about the scientific journey behind GLP-1 therapies, multiagonist drug development, and future obesity treatments. We explore glucagon, GIP, triple agonists, and emerging innovations shaping metabolic medicine. Listen now on all major platforms! "For decades, glucagon was viewed primarily as a hormone that raises blood glucose. Research later revealed that glucagon could also promote weight reduction and improve liver metabolism when balanced appropriately with GLP-1 activity." Meet the guest: Dr. Richard DiMarchi [https://www.linkedin.com/in/richard-dimarchi-642a5710/] is a Distinguished Professor at Indiana University and a recognized leader in peptide therapeutics, diabetes research, and obesity medicine. His work contributed to major advances in insulin, glucagon, and multiagonist therapies, while also helping establish several biotechnology companies. Dr. DiMarchi continues to advance innovation in the treatment of metabolic diseases through research and translational science. Listen to Dr. Richard DiMarchi on The GLP-1 Podcast Show, available on all major platforms. What you will learn: * (00:00) Highlight * (01:19) Introduction * (05:31) GLP-1 evolution * (09:16) Multiagonist design * (15:46) Glucagon controversy * (17:42) GIP role * (24:32) Future treatments * (30:13) Final Questions 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: The GLP-1 Podcast Show [https://www.wisenetix.com/glp1] Instagram: The GLP-1 Podcast Show [https://www.instagram.com/theglp1podcast/] LinkedIn: The GLP-1 Podcast Show [https://www.linkedin.com/showcase/the-glp-1-podcast-show/]

Dr. Sandra Christensen: Preserving Muscle During GLP-1 Treatment | Ep. 09

In this episode of The GLP-1 Podcast Show, I speak with Dr. Sandra Christensen, obesity medicine specialist and founder of Integrative Medical Weight Management. We examine how GLP-1 therapies impact body composition beyond total weight loss. Dr. Christensen explores fat-free mass reduction, muscle and bone considerations, and clinical risks. She also addresses nutrition strategies, resistance training, and the importance of structured monitoring and personalized care. Listen now on all major platforms! "When evaluating weight reduction outcomes, it is essential to distinguish between fat mass and fat-free mass, because each component has different physiological roles and clinical implications." Meet the guest: Dr. Sandra Christensen [https://www.linkedin.com/in/sandra-christensen/] is an obesity medicine specialist and founder of Integrative Medical Weight Management in Seattle. She holds advanced certification in obesity medicine and serves as a trustee for the Obesity Medicine Association and president of the Washington Obesity Society. Her work focuses on clinical strategies, patient care, and education in obesity treatment. Learn more from Dr. Sandra Christensen on The GLP-1 Podcast Show, available on all major platforms. What you will learn: * (00:00) Highlight * (01:07) Introduction * (02:34) Body composition * (04:09) Fat-free mass * (07:46) Protein strategies * (12:08) Resistance training * (14:51) Monitoring tools * (25:47) Final Questions 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: The GLP-1 Podcast Show [https://www.wisenetix.com/glp1] Instagram: The GLP-1 Podcast Show [https://www.instagram.com/theglp1podcast/] LinkedIn: The GLP-1 Podcast Show [https://www.linkedin.com/showcase/the-glp-1-podcast-show/]

Dr. Jason Itri: GLP-1 Microdosing Strategy | Ep. 08

In this episode of The GLP-1 Podcast Show, I speak with Dr. Jason Itri, Founder of Longevity Health Clinic, about how GLP-1 therapies extend beyond weight loss into cardiometabolic optimization. We examine microdosing strategies, insulin resistance, inflammation pathways, and sustainable habit formation through precision prescribing. Dr. Itri highlights practical clinical applications for long-term metabolic health. Listen now on all major platforms! "Lower dose GLP-1 strategies can improve control over dietary habits by reducing impulsive food decisions and supporting consistent behavioral patterns over extended periods." Meet the guest: Dr. Jason Itri [https://www.linkedin.com/in/jason-itri-20962326/] is a physician and the founder of Longevity Health Clinic in Virginia, specializing in cardiometabolic health, hormone optimization, and GLP-1 therapies. His work integrates biomarker testing with root-cause physiology to improve metabolic outcomes and reduce long-term disease risk. His clinical focus aligns with advancing precision approaches in obesity medicine and metabolic care.  What you will learn: * (00:00) Highlight * (01:08) Introduction * (05:09) Microdosing strategy * (07:27) Habit control * (15:11) Risk markers * (17:11) Insulin resistance * (29:10) Muscle loss * (32:20) Final Questions 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: The GLP-1 Podcast Show [https://www.wisenetix.com/glp1] Instagram: The GLP-1 Podcast Show [https://www.instagram.com/theglp1podcast/] LinkedIn: The GLP-1 Podcast Show [https://www.linkedin.com/showcase/the-glp-1-podcast-show/]

Dr. Catherine Toomer: GLP-1 Dosing Strategy | Ep. 07

In this episode of The GLP-1 Podcast Show, I speak with Dr. Catherine Toomer, founder of Total Weight Care Institute and a family medicine physician specializing in metabolic disease. The discussion examines long-term clinical experience using GLP-1 therapies, including dosing strategies, metabolic regulation, and patient-centered obesity care. She also explores insulin resistance, brain signaling, and emerging therapeutic applications. Listen now on all major platforms! “Appetite regulation is strongly influenced by brain signaling pathways, and correcting metabolic signaling often changes hunger perception and eating behavior without relying on willpower alone.” Meet the guest: Dr. Catherine Toomer [https://www.linkedin.com/in/drtoomer/] is a family medicine physician and founder of Total Weight Care Institute, with more than fifteen years of clinical experience using GLP-1 therapies to address metabolic disease and obesity. Her work focuses on correcting metabolic dysregulation through evidence-based medical strategies and personalized care.  What you will learn: * (00:00) Highlight * (00:31) Introduction * (01:52) Metabolic disease drivers * (05:33) Personalized dosing strategy * (07:17) Managing side effects * (19:44) Brain appetite signaling * (22:40) Future applications * (24:50) Final Questions 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: The GLP-1 Podcast Show [https://www.wisenetix.com/glp1] Instagram: The GLP-1 Podcast Show [https://www.instagram.com/theglp1podcast/] LinkedIn: The GLP-1 Podcast Show [https://www.linkedin.com/showcase/the-glp-1-podcast-show/]

Dr. Caroline Apovian: GLP-1 Game Changers | Ep. 06

In this episode of The GLP-1 Podcast Show, I speak with Dr. Caroline Apovian, Professor of Medicine at Harvard Medical School and Co Director of the Center for Weight Management and Wellness at Brigham and Women’s Hospital, about the evolution of obesity treatment. We discuss why obesity is a chronic disease, how GLP-1 based therapies have changed clinical outcomes, and how they compare with lifestyle intervention and metabolic surgery. Dr. Apovian also addresses stigma, access barriers, and the risks of cosmetic use. Listen now on all major platforms! "Stigma surrounding obesity has forced clinicians to repeatedly prove that treating obesity also prevents cardiovascular disease and diabetes." Meet the guest: Dr. Caroline Apovian [https://www.linkedin.com/in/drapovian/] is Professor of Medicine at Harvard Medical School and Co Director of the Center for Weight Management and Wellness at Brigham and Women’s Hospital. A founding leader in obesity medicine, her research focuses on adipose tissue inflammation, cardiovascular risk, metabolic surgery, and pharmacotherapy for obesity.  To hear Dr. Allison's actual remarks, view the recorded debate here [https://opentodebate.substack.com/p/prescription-weight-loss-drugs-for-all]! What you will learn: * (00:00) Highlight * (01:23) Introduction * (04:41) GLP-1 overview * (07:55) Obesity disease model * (13:35) Treatment comparisons * (19:59) Cardiovascular outcomes * (25:44) Cosmetic use debate * (33:22) Final Questions 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: The GLP-1 Podcast Show [https://www.wisenetix.com/glp1] Instagram: The GLP-1 Podcast Show [https://www.instagram.com/theglp1podcast/] LinkedIn: The GLP-1 Podcast Show [https://www.linkedin.com/showcase/the-glp-1-podcast-show/]